Catalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.17, $0.08 better than the analyst estimate of $0.09. Revenue for the quarter came in at $36.4 million versus the consensus estimate of $31.51 million.

For earnings history and earnings-related data on Catalyst Pharmaceuticals (CPRX) click here.